S1PR1 inhibitors, such as siponimod and ponesimod, are already in clinical use for the treatment of multiple sclerosis, and there is potential for their application in modulating responses to CD20 antibody immunotherapy in lymphoma patients [77,78,79]. This evidence concerns the gene S1PR1 and multiple sclerosis.